Pharmacokinetics and pharmacodynamics of a single dose of zoledronate in healthy dogs

Journal of Veterinary Pharmacology and Therapeutics

Volumn 30, Issue 5, 2007, Pages 492-495

  Martin Jimenez T ^a   De Lorimier, L P ^b   Fan, T M ^b   Freise, K J ^c  

^a UNIVERSITY OF TENNESSEE   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; ZOLEDRONIC ACID;

AREA UNDER THE CURVE; ARTICLE; BONE DISEASE; CONTINUOUS INFUSION; DOG; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EXCRETION; DRUG MECHANISM; NEPHROTOXICITY; NONHUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ANIMALS; AREA UNDER CURVE; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DOGS; IMIDAZOLES; INJECTIONS, INTRAVENOUS; MALE;

CANIS FAMILIARIS;

EID: 34548379047     PISSN: 01407783     EISSN: 13652885     Source Type: Journal    
DOI: 10.1111/j.1365-2885.2007.00883.x     Document Type: Article

References (16)

1. Agnello, K.A., Trumble, T.N., Chambers, J.N., Seewald, W. Budsberg, S.C. (2005) Effects of zoledronate on markers of bone metabolism and subchondral bone mineral density in dogs with experimentally induced cruciate-deficient osteoarthritis. American Journal of Veterinary Research, 66, 1487 1495.
2. Allen, L.C., Allen, M.J., Breur, G.J., Hoffmann, W.E. Richardson, D.C. (2000a) A comparison of two techniques for the determination of serum bone-specific alkaline phosphatase activity in dogs. Research in Veterinary Science, 68, 231 235.
3. Allen, M.J., Allen, L.C., Hoffmann, W.E., Richardson, D.C. Breur, G.J. (2000b) Urinary markers of type I collagen degradation in the dog. Research in Veterinary Science, 69, 123 127.
4. Berruti, A., Dogliotti, L., Gorzegno, G., Torta, M., Tampellini, M., Tucci, M., Cerutti, S., Frezet, M.M., Stivanello, M., Sacchetto, G. Angeli, A. (1999) Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases. Clinical Chemistry, 45 (8 Pt 1 1240 1247.
5. Chen, T., Berenson, J., Vescio, R., Swift, R., Gilchick, A., Goodin, S., LoRusso, P., Ma, P., Ravera, C., Deckert, F., Schran, H., Seaman, J. Skerjanec, A. (2002) Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. Journal of Clinical Pharmacology, 42, 1228 1236.
6. Coleman, R.E., Whitaker, K.B., Moss, D.W., Mashiter, G., Fogelman, I. Rubens, R.D. (1988) Biochemical prediction of response of bone metastases to treatment. British Journal of Cancer, 58, 205 210.
7. Coleman, R.E., Major, P., Lipton, A., Brown, J.E., Lee, K.A., Smith, M., Saad, F., Zheng, M., Hei, Y.J., Seaman, J. Cook, R. (2005) Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. Journal of Clinical Oncology, 23, 4925 4935.
8. Legay, F., Gauron, S., Deckert, F., Gosset, G., Pfaar, U., Ravera, C., Wiegand, H. Schran, H. (2002) Development and validation of a highly sensitive RIA for zoledronic acid, a new potent heterocyclic bisphosphonate, in human serum, plasma and urine. Journal of Pharmaceutical and Biomedical Analysis, 30, 897 911.
9. Lipton, A. (2005) New therapeutic agents for the treatment of bone diseases. Expert Opinion on Biological Theraphy, 5, 817 832.
10. Markowitz, G.S., Fine, P.L., Stack, J.I., Kunis, C.L., Radhakrishnan, J., Palecki, W., Park, J., Nasr, S.H., Hoh, S., Siegel, D.S. D'Agati, V.D. (2003) Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney International, 64, 281 289.
11. Pectasides, D., Nikolaou, M., Farmakis, D., Kanakis, I., Gaglia, A., Kountourakis, P., Karamanos, N.K., Economopoulos, T. Raptis, S.A. (2005) Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid. Anticancer Research, 25, 1457 1463.
12. Pfister, T., Atzpodien, E. Bauss, F. (2003) The renal effects of minimally nephrotoxic doses of ibandronate and zoledronate following single and intermittent intravenous administration in rats. Toxicology, 191, 159 167.
13. Skerjanec, A., Berenson, J., Hsu, C., Major, P., Miller, W.H. Jr., Ravera, C., Schran, H., Seaman, J. Waldmeier, F. (2003) The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function. Journal of Clinical Pharmacology, 43, 154 162.
14. Usui, T., Watanabe, T. Higuchi, S. (1995) Pharmacokinetics of YM175, a new bisphosphonate, in rats and dogs. Drug Metabolism and Disposition, 23, 1214 1219.
15. Veng-Pedersen, P. (2001) Noncompartmentally-based pharmacokinetic modeling. Advanced Drug Delivery Reviews, 48, 265 300.
16. Voskaridou, E., Anagnostopoulos, A., Konstantopoulos, K., Stoupa, E., Spyropoulou, E., Kiamouris, C. Terpos, E. (2006) Zoledronic acid for the treatment of osteoporosis in patients with beta-thalassemia: results from a single-center, randomized, placebo-controlled trial. Haematologica, 91, 1193 1202.